Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: PTC Therapeutics, Inc.

Market Cap 6.55B 5.71B 5.28B 4.95B 9.27B 618B 9.34B 62.72B 24.3B 304B 24.59B 24.06B 1,057B P/E 2026 *
89.1x
P/E 2027 * 31.6x
Enterprise Value 4.77B 4.16B 3.84B 3.6B 6.75B 450B 6.8B 45.64B 17.69B 221B 17.89B 17.51B 769B EV / Sales 2026 *
4.06x
EV / Sales 2027 * 3.59x
Free-Float
92.62%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 54 2023-03-21
Director of Finance/CFO 41 2023-07-12
Chief Tech/Sci/R&D Officer - 2017-09-30
Director TitleAgeSince
Chairman 74 2004-10-31
Chairman 80 1998-03-30
Director/Board Member 65 2005-11-30
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 6.55B
-1.21%-3.04%+39.94%+145.38% 980B
-2.48%-5.18%+51.52%+39.07% 550B
-2.14%-4.94%+16.71%+56.15% 382B
+0.25%-3.09%+23.00%+15.81% 316B
+0.61%-1.69%+25.42%+13.64% 272B
+0.22%-3.10%+24.25%+30.21% 268B
+4.59%+1.98%-40.02%-45.89% 199B
-1.19%-4.95%+16.56%+47.00% 182B
-1.35%-1.46%+14.59%+56.94% 154B
Average -0.27%-3.02%+19.11%+39.81% 366.93B
Weighted average by Cap. -0.78%-3.68%+27.80%+63.70%

Financials

2026 *2027 *
Net sales 1.17B 1.02B 946M 887M 1.66B 111B 1.67B 11.23B 4.35B 54.47B 4.4B 4.31B 189B 1.31B 1.14B 1.06B 992M 1.86B 124B 1.87B 12.57B 4.87B 60.93B 4.93B 4.82B 212B
Net income 65.46M 57.08M 52.78M 49.47M 92.63M 6.17B 93.36M 627M 243M 3.04B 246M 240M 10.56B 178M 155M 143M 134M 252M 16.78B 254M 1.7B 660M 8.26B 668M 653M 28.69B
Net Debt -1.78B -1.56B -1.44B -1.35B -2.52B -168B -2.54B -17.08B -6.62B -82.82B -6.69B -6.55B -288B -1.84B -1.6B -1.48B -1.39B -2.6B -174B -2.62B -17.62B -6.83B -85.44B -6.91B -6.76B -297B
Logo PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
78.98USD
Average target price
93.93USD
Spread / Average Target
+18.93%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!